A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

Brief description of study

This study is designed for patients diagnosed with advanced solid tumors. This is a study for the first time testing of a new medicine called AZD9592 in human subjects for people with Epidemermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial transition factor (cMET) expressing tumors, initially Non-small cell lung cancer (NSCLC) EGFR mut(L858R/ex19del) and wild type, as well as Head and Neck squamous cell carcinoma (HNSCC). The study will focus on lung cancer and head and neck cancer, and will also look at how well AZD9592 works, how the body processes it, and how it affects the immune system. The study will look at how safe and tolerable AZD9592 is, and will identify the best doseage amount for people for future studies.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.